16-17 September 2015
Establishing Effective Pharmacovigilance and Risk Management Strategies to Comply with Global Regulatory Standards to Ensure Drug Safety.
Increased public scrutiny has been driving the focus on drug safety surveillance. Pharmaceutical and Biopharmaceutical professionals continue to face the ongoing pressures from government entities and public concern. With the utmost importance on patient safety and regulatory compliance, pharmaceutical firms must effectively monitor and detect adverse event reports and comply with all regulatory standards.
Attendees of the 5th Annual Pharmacovigilance, Risk Management & AER Conference will gain a comprehensive understanding of the challenges key leaders working in pharmacovigilance and risk management are currently facing. They will learn how to manage changes in global regulatory standards and the impact on risk management and postmarket safety surveillance. Additionally, emerging challenges such as social media and signal detection and its role in pharmacovigilance across the product lifecycle will be discussed.
Dr David Balderson, Vice President of Global Safety Operations, Sciformix Corporation will be moderating a panel on “Social Media: The Next Challenge in Adverse Event Reporting”. Panelists include:
– Julie Thomas, Senior Director, Safety Evaluation and Reporting, Johnson & Johnson
– Krisztina Debreczeni, Group Medical Director, Medical Safety Review Global Pharmacovigilance and Epidemiology, Bristol-Meyers Squibb Co.
Meet us there! Schedule a meeting.